Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy

PLoS Medicine

Volumn 5, Issue 5, 2008, Pages 0777-0788

  Bisson, Gregory P ^a   Gross, Robert ^a   Bellamy, Scarlett ^a   Chittams, Jesse ^a   Hislop, Michael ^b   Regensberg, Leon ^b   Frank, Ian ^a   Maartens, Gary ^c   Nachega, Jean B ^c,d,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Aid for AIDS Disease Management Program Ltd   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACY; ROC CURVE; TREATMENT FAILURE; VIREMIA; VIRUS LOAD; AGED; CD4+ T LYMPHOCYTE; CYTOLOGY; LYMPHOCYTE COUNT; MIDDLE AGED; PREDICTIVE VALUE; PRESCRIPTION; STATISTICS;

ADULT; AGED; ANTI-HIV AGENTS; AREA UNDER CURVE; CD4-POSITIVE T-LYMPHOCYTES; DRUG PRESCRIPTIONS; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACIES; PREDICTIVE VALUE OF TESTS;

EID: 44449123557     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050109     Document Type: Article

References (36)

1. [No author listed] (2005) Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS. World Health Organization, United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS, Medecins Sans Frontieres.
2. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, et al. (1995) Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 122: 401-408.
3. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, et al. (1994) Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 121: 263-268.
4. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, et al. (2005) Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 19: 1081-1089.
5. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, et al. (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296: 827-843.
6. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, et al. (2007) HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 44: 128-134.
7. WHO (2006) Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2006 Revision. Geneva: WHO. Available: http://www.who.int/hiv/pub/guidelines/ artadultguidelines. pdf. Accessed 23 April 2008.
8. WHO (2005) CD4+ T-cell enumeration technologies: technical information. Geneva: WHO and UNAIDS. Available: http://www.who.int/diagnostics_laboratory/ CD4_Technical_Advice_ENG.pdf. Accessed 14 April 2008.
9. Cohen J (2004) Monitoring treatment: at what cost? Science 304: 1936.
10. Montaner JS, Hogg RS (2007) Hungering for HAART. Ann Intern Med 146: 609-610.
11. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30.
12. Nachega JB, Hislop M, Dowdy D, Chaisson R, Regensberg L, et al. (2007) Adherence to non-nucleoside reverse transcriptase-based hiv therapy and virologic outcomes. Ann Intern Med 146: 564-573.
13. Gross R, Bilker WB, Friedman HM, Strom BL (2001) Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 15: 2109-2117.
14. Bangsberg DR (2006) Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43: 939-941.
15. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS (2000) Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 23: 360-361.
16. Grossberg R, Zhang Y, Gross R (2004) A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 57: 1107-1110.
17. Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, et al. (2006) Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 20: 1613-1619.
18. Colebunders R, Moses KR, Laurence J, Shihab HM, Semitala F, et al. (2006) A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis 6: 53-59.
19. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, et al. (2003) Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362: 679-686.
20. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78-84.
21. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
22. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, et al. (2005) Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 40: 336-343.
23. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama 296: 782-793.
24. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334.
25. Hosmer DW, Lemeshow S (2000) Applied logistic regression. New York: Wiley. xii, 373 p.
26. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
27. Ohman EM, Granger CB, Harrington RA, Lee KL (2000) Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 284: 876-878.
28. Harrell FE Jr., Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247: 2543-2546.
29. Efron B, Tibshirani R (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1: 54-77.
30. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, et al. (2004) Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 190: 148-155.
31. Levy RW, Rayner CR, Fairley CK, Kong DC, Mijch A, et al. (2004) Multidisciplinary HIV adherence intervention: a randomized study. AIDS Patient Care STDS 18: 728-735.
32. Dieckhaus KD, Odesina V (2007) Outcomes of a multifaceted medication adherence intervention for HIV-positive patients. AIDS Patient Care STDS 21: 81-91.
33. Moore DM, Mermin J, Awor A, Yip B, Hogg RS, et al. (2006) Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 43: 436-439.
34. Nieuwkerk PT, Oort FJ (2005) Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr 38: 445-448.
35. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, et al. (2006) Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 10: 227-245.
36. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, et al. (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17: 1925-1932.